Von Hoff DD - Search Results

1

Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.

Dragovich T, Burris H 3rd, Loehrer P, Von Hoff DD, Chow S, Stratton S, Green S, Obregon Y, Alvarez I, Gordon M. Dragovich T, et al. Among authors: von hoff dd. Am J Clin Oncol. 2008 Apr;31(2):157-62. doi: 10.1097/COC.0b013e31815878c9. Am J Clin Oncol. 2008. PMID: 18391600 Clinical Trial.

2

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.

Wall JG, Burris HA 3rd, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G, et al. Wall JG, et al. Among authors: von hoff dd. Anticancer Drugs. 1992 Aug;3(4):337-45. doi: 10.1097/00001813-199208000-00004. Anticancer Drugs. 1992. PMID: 1330081 Clinical Trial.

3

Clinical trials with the topoisomerase I inhibitors.

Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD. Burris HA, et al. Among authors: von hoff dd. Semin Oncol. 1992 Dec;19(6):663-9. Semin Oncol. 1992. PMID: 1334279 Review.

4

Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study.

Von Hoff DD, Green S, Surwit EA, Hannigan EV, Alberts DS. Von Hoff DD, et al. Am J Clin Oncol. 1990 Oct;13(5):433-5. doi: 10.1097/00000421-199010000-00014. Am J Clin Oncol. 1990. PMID: 1699401 Clinical Trial.

5

Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group Study.

Von Hoff DD, Green S, Alberts DS, Stock-Novack DL, Surwit EA, Miller TP, Stephens RL. Von Hoff DD, et al. Am J Clin Oncol. 1991 Jun;14(3):193-4. doi: 10.1097/00000421-199106000-00004. Am J Clin Oncol. 1991. PMID: 1709556 Clinical Trial.

6

Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.

Von Hoff DD, Green SJ, Neidhart JA, Fabian C, Budd T, Boyd JF, Osborne CK. Von Hoff DD, et al. Invest New Drugs. 1991 Feb;9(1):87-8. doi: 10.1007/BF00194553. Invest New Drugs. 1991. PMID: 2026487 Clinical Trial. No abstract available.

7

Phase II trial of vindesine in patients with squamous cell cancer of the head and neck.

Sledge GW Jr, Clark GM, Griffin C, Mattox DE, Von Hoff DD. Sledge GW Jr, et al. Among authors: von hoff dd. Am J Clin Oncol. 1984 Jun;7(3):209-11. doi: 10.1097/00000421-198406000-00004. Am J Clin Oncol. 1984. PMID: 6731343

8

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.

Burris HA 3rd, Awada A, Kuhn JG, Eckardt JR, Cobb PW, Rinaldi DA, Fields S, Smith L, Von Hoff DD. Burris HA 3rd, et al. Among authors: von hoff dd. Anticancer Drugs. 1994 Aug;5(4):394-402. doi: 10.1097/00001813-199408000-00002. Anticancer Drugs. 1994. PMID: 7949242 Clinical Trial.

9

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.

Shimada Y, Rothenberg M, Hilsenbeck SG, Burris HA 3rd, Degen D, Von Hoff DD. Shimada Y, et al. Among authors: von hoff dd. Anticancer Drugs. 1994 Apr;5(2):202-6. doi: 10.1097/00001813-199404000-00011. Anticancer Drugs. 1994. PMID: 8049503

10

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.

O'Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, Satterlee WG, Tarassoff PG, Von Hoff DD. O'Rourke TJ, et al. Among authors: von hoff dd. Eur J Cancer. 1994;30A(3):417-8. doi: 10.1016/0959-8049(94)90276-3. Eur J Cancer. 1994. PMID: 8204374 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

772 results

Search Page

Filters